Literature DB >> 21351740

Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release.

Saugata Hazra1, Andrzej Szewczak, Stephan Ort, Manfred Konrad, Arnon Lavie.   

Abstract

Deoxycytidine kinase (dCK) uses either ATP or UTP as a phosphoryl donor to catalyze the phosphorylation of nucleoside acceptors. The kinetic properties of human dCK are modulated in vivo by phosphorylation of serine 74. This residue is a part of the insert region and is distant from the active site. Replacing the serine with a glutamic acid (S74E variant) can mimic phosphorylation of Ser74. To understand how phosphorylation affects the catalytic properties of dCK, we examined the S74E variant of dCK both structurally and kinetically. We observe that the presence of a glutamic acid at position 74 favors the adoption by the enzyme of the open conformation. Glu74 stabilizes the open conformation by directly interacting with the indole side chain of Trp58, a residue that is in the proximity of the base of the nucleoside substrate. The open dCK conformation is competent for the binding of nucleoside but not for phosphoryl transfer. In contrast, the closed conformation is competent for phosphoryl transfer but not for product release. Thus, dCK must make the transition between the open and closed states during the catalytic cycle. We propose a reaction scheme for dCK that incorporates the transition between the open and closed states, and this serves to rationalize the observed kinetic differences between wild-type dCK and the S74E variant.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21351740      PMCID: PMC3071448          DOI: 10.1021/bi2001032

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

1.  Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues .

Authors:  Saugata Hazra; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2010-08-10       Impact factor: 3.162

2.  Kinetic analysis of human deoxycytidine kinase with the true phosphate donor uridine triphosphate.

Authors:  T L Hughes; T M Hahn; K K Reynolds; D S Shewach
Journal:  Biochemistry       Date:  1997-06-17       Impact factor: 3.162

3.  Identification of phosphorylation sites on human deoxycytidine kinase after overexpression in eucaryotic cells.

Authors:  C Smal; D Vertommen; L Bertrand; M H Rider; E van den Neste; F Bontemps
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2006       Impact factor: 1.381

4.  Functional studies of active-site mutants from Drosophila melanogaster deoxyribonucleoside kinase. Investigations of the putative catalytic glutamate-arginine pair and of residues responsible for substrate specificity.

Authors:  Louise Egeblad-Welin; Yonathan Sonntag; Hans Eklund; Birgitte Munch-Petersen
Journal:  FEBS J       Date:  2007-03       Impact factor: 5.542

5.  Fluorescence energy transfer studies of human deoxycytidine kinase: role of cysteine 185 in the conformational changes that occur upon substrate binding.

Authors:  Rajam S Mani; Elena V Usova; Carol E Cass; Staffan Eriksson
Journal:  Biochemistry       Date:  2006-03-21       Impact factor: 3.162

6.  Nucleotide specificity of human deoxycytidine kinase.

Authors:  D S Shewach; K K Reynolds; L Hertel
Journal:  Mol Pharmacol       Date:  1992-09       Impact factor: 4.436

7.  Elucidation of different binding modes of purine nucleosides to human deoxycytidine kinase.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2008-06-21       Impact factor: 7.446

8.  Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Arnon Lavie
Journal:  J Med Chem       Date:  2007-05-27       Impact factor: 7.446

9.  Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase.

Authors:  Saugata Hazra; Elisabetta Sabini; Stephan Ort; Manfred Konrad; Arnon Lavie
Journal:  Biochemistry       Date:  2009-02-17       Impact factor: 3.162

10.  Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase.

Authors:  Elisabetta Sabini; Saugata Hazra; Manfred Konrad; Stephen K Burley; Arnon Lavie
Journal:  Nucleic Acids Res       Date:  2006-12-07       Impact factor: 16.971

View more
  14 in total

1.  Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe.

Authors:  Dean O Campbell; Shahriar S Yaghoubi; Ying Su; Jason T Lee; Martin S Auerbach; Harvey Herschman; Nagichettiar Satyamurthy; Johannes Czernin; Arnon Lavie; Caius G Radu
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

2.  Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.

Authors:  Anton Neschadim; James C M Wang; Takeya Sato; Daniel H Fowler; Arnon Lavie; Jeffrey A Medin
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

3.  A phosphotyrosine switch for cargo sequestration at clathrin-coated buds.

Authors:  Souvik Chakraborty; Perunthottathu K Umasankar; G Michael Preston; Puneet Khandelwal; Gerard Apodaca; Simon C Watkins; Linton M Traub
Journal:  J Biol Chem       Date:  2014-05-05       Impact factor: 5.157

4.  Structural characterization of new deoxycytidine kinase inhibitors rationalizes the affinity-determining moieties of the molecules.

Authors:  Julian Nomme; Jennifer M Murphy; Ying Su; Natasha D Sansone; Amanda L Armijo; Steven T Olson; Caius Radu; Arnon Lavie
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-12-24

5.  Solution structure and functional investigation of human guanylate kinase reveals allosteric networking and a crucial role for the enzyme in cancer.

Authors:  Nazimuddin Khan; Parag P Shah; David Ban; Pablo Trigo-Mouriño; Marta G Carneiro; Lynn DeLeeuw; William L Dean; John O Trent; Levi J Beverly; Manfred Konrad; Donghan Lee; T Michael Sabo
Journal:  J Biol Chem       Date:  2019-06-14       Impact factor: 5.157

6.  Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.

Authors:  Benigno C Valdez; Guiyun Wang; David Murray; Yago Nieto; Yang Li; Jatin Shah; Francesco Turturro; Michael Wang; Donna M Weber; Richard E Champlin; Muzaffar H Qazilbash; Borje S Andersson
Journal:  Exp Hematol       Date:  2013-05-03       Impact factor: 3.084

7.  Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase.

Authors:  Safiatou T Coulibaly; Paola Rossolillo; Flore Winter; Franziska K Kretzschmar; Mélanie Brayé; Darren P Martin; Daniela Lener; Matteo Negroni
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

8.  Retrovolution: HIV-driven evolution of cellular genes and improvement of anticancer drug activation.

Authors:  Paola Rossolillo; Flore Winter; Etienne Simon-Loriere; Sarah Gallois-Montbrun; Matteo Negroni
Journal:  PLoS Genet       Date:  2012-08-23       Impact factor: 5.917

Review 9.  New insights into the synergism of nucleoside analogs with radiotherapy.

Authors:  Michael W Lee; William B Parker; Bo Xu
Journal:  Radiat Oncol       Date:  2013-09-26       Impact factor: 3.481

10.  Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance.

Authors:  Yuri L Bunimovich; Evan Nair-Gill; Mireille Riedinger; Melissa N McCracken; Donghui Cheng; Jami McLaughlin; Caius G Radu; Owen N Witte
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.